Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 2, 2013, Pages 323-328

  Chamorro, Julián G ^a   Castagnino, Jorge P ^a   Musella, Rosa M ^a   Nogueras, Mabel ^a   Aranda, Federico M ^a   Frías, Ana ^a   Visca, Mabel ^a   Aidar, Omar ^a   Perés, Silvia ^a   De Larrañaga, Gabriela F ^a  

^a Hemostasis and Thrombosis Laboratory Hospital of Infectious Diseases Dr F J Muñiz   (Argentina)

Author keywords

Arylamine N acetyltransferase 2; Cytochrome P450 2E1; Drug toxicity; Isoniazid; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARGENTINA; ARTICLE; ARYLAMINE ACETYLTRANSFERASE GENE; BOLIVIA; CONTROLLED STUDY; CYTOCHROME P450 2E1 GENE; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENDER; GENE FREQUENCY; GENETIC ANALYSIS; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SLOW ACETYLATOR PROFILE; TUBERCULOSIS;

EID: 84872788104     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12069     Document Type: Article

References (34)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO report 2006. WHO/HTM/TB/2006.362. Geneva, Switzerland: World Health Organization, 2006.
2. World Health Organization. Actions for life towards a world free of tuberculosis: the global plan to stop TB 2006-2015. WHO/HTM/STB/2006.35. Geneva, Switzerland: World Health Organization, 2006.
3. Bossio JC, Fernandez HR, Arias SJ etal. NOTIFICACIÓN DE CASOS DE TUBERCULOSIS EN LA REPUBLICA ARGENTINA PERÍODO 1980-2009. In: Nación. MdsPdl, editor. 2010.
4. Higuchi N, Tahara N, Yanagihara K etal. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J. Gastroenterol. 2007; 13: 6003-6008.
5. Yamada S, Tang M, Richardson K etal. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009; 10: 1433-1445.
6. Cho HJ, Koh WJ, Ryu YJ etal. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87: 551-556.
7. Possuelo LG, Castelan JA, de Brito TC etal. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol. 2008; 64: 673-681.
8. Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 2008; 9: 21-35.
9. Timbrell JA. Studies on the role of acetylhydrazine in isoniazid hepatotoxicity. Arch. Toxicol. Suppl. 1979; 2: 1-8.
10. Noda A, Hsu KY, Noda H, Yamamoto Y, Kurozumi T. Is isoniazid-hepatotoxicity induced by the metabolite, hydrazine? J. UOEH 1983; 5: 183-190.
11. Lauterburg BH, Smith CV, Todd EL, Mitchell JR. Oxidation of hydrazine metabolites formed from isoniazid. Clin. Pharmacol. Ther. 1985; 38: 566-571.
12. Ohno M, Yamaguchi I, Yamamoto I etal. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 2000; 4: 256-261.
13. Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J. Toxicol. Environ. Health B Crit. Rev. 2009; 12: 440-472.
14. Bailliet G, Santos MR, Alfaro EL etal. Allele and genotype frequencies of metabolic genes in Native Americans from Argentina and Paraguay. Mutat. Res. 2007; 627: 171-177.
15. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 1996; 6: 203-211.
16. Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int. J. Tuberc. Lung Dis. 2010; 14: 622-626.
17. Ryan DE, Iida S, Wood AW, Thomas PE, Lieber CS, Levin W. Characterization of three highly purified cytochromes P-450 from hepatic microsomes of adult male rats. J. Biol. Chem. 1984; 259: 1239-1250.
18. Neafsey P, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in CYP2E1: population distribution of CYP2E1 activity. J. Toxicol. Environ. Health B Crit. Rev. 2009; 12: 362-388.
19. Vuilleumier N, Rossier MF, Chiappe A etal. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol. 2006; 62: 423-429.
20. Huang YS, Chern HD, Su WJ etal. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
21. Munaka M, Kohshi K, Kawamoto T etal. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2003; 129: 355-360.
22. Chamorro JG, Castagnino JP, Musella RM, Frías A, Aranda FM, de Larrañaga GF. The distribution of allelic and genotypic frequencies of N-Acetyltransferase-2 variants in an Argentine population. J. Infect. Dev. Ctries. 2012; 6: 671-674.
23. Saukkonen JJ, Cohn DL, Jasmer RM etal. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 2006; 174: 935-952.
24. Stephens EA, Taylor JA, Kaplan N etal. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994; 4: 185-192.
25. Batra J, Sharma SK, Ghosh B. Arylamine N-acetyltransferase gene polymorphisms: markers for atopic asthma, serum IgE and blood eosinophil counts. Pharmacogenomics 2006; 7: 673-682.
26. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am. J. Hum. Genet. 1993; 52: 827-834.
27. Huang YS, Chern HD, Su WJ etal. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
28. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 2003; 167: 1472-1477.
29. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber. Lung Dis. 1996; 77: 335-340.
30. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int. J. Tuberc. Lung Dis. 2002; 6: 699-705.
31. Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase 2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J. Gastroenterol. Hepatol. 2011; 26: 312-318.
32. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int. J. Tuberc. Lung Dis. 2012; 16: 589-595.
33. Catelli ML, Alvarez-Iglesias V, Gomez-Carballa A etal. The impact of modern migrations on present-day multi-ethnic Argentina as recorded on the mitochondrial DNA genome. BMC Genet. 2011; 12: 77-90.
34. Corach D, Lao O, Bobillo C etal. Inferring continental ancestry of Argentineans from autosomal, Y-chromosomal and mitochondrial DNA. Ann. Hum. Genet. 2010; 74: 65-76.